Study S003095

This Trial is Conducted in the United State of America. The Aim of This Trial is to Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity

ClinicalTrials.gov record

Registration

Registration: NCT02941042
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 49
Start: 2016-10-10
Primary completion: 2017-09-30
Lead sponsor: Novo Nordisk A/S
Conditions: Metabolism and Nutrition Disorder; Obesity
Interventions: DRUG:NNC9204-1177; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1173-8190

Registered primary outcomes

Number of treatment emergent adverse events (TEAEs) [From time of dosing (day 1) until completion of the follow-up visit (day 39)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.